Journal Article

Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of α-1 Antitrypsin Deficiency

Greer, Cynthia, Wang, Ziqiong, Flotte, Terence R., Shultz, Leonard D., Kay, Mark A., Mueller, Christian, Borel, Florie, Tang, Qiushi, Barzel, Adi, Brehm, Michael A., Greiner, Dale L., Gernoux, Gwladys

2017

Overview

Hepatocytes represent an important target for gene therapy and editing of single-gene disorders. In α-1 antitrypsin (AAT) deficiency, one missense mutation results in impaired secretion of AAT. In most patients, lung damage occurs due to a lack of AAT-mediated protection of lung elastin from neutrophil elastase. In some patients, accumulation of misfolded PiZ mutant AAT protein triggers hepatocyte injury, leading to inflammation and cirrhosis. We hypothesized that correcting the Z mutant defect in hepatocytes would confer a selective advantage for repopulation of hepatocytes within an intact liver. A human PiZ allele was crossed onto an immune-deficient (NSG) strain to create a recipient strain (NSG-PiZ) for human hepatocyte xenotransplantation. Results indicate that NSG-PiZ recipients support heightened engraftment of normal human primary hepatocytes as compared with NSG recipients. This model can therefore be used to test hepatocyte cell therapies for AATD, but more broadly it serves as a simple, highly reproducible liver xenograft model. Finally, a promoterless adeno-associated virus (AAV) vector, expressing a wild-type AAT and a synthetic miRNA to silence the endogenous allele, was integrated into the albumin locus. This gene-editing approach leads to a selective advantage of edited hepatocytes, by silencing the mutant protein and augmenting normal AAT production, and improvement of the liver pathology. Borel et al. describe two studies based on misfolded human α-1 antitrypsin (A1AT). First, when A1AT is expressed in livers of NSG, mice it allows for reproducible engraftment of human hepatocytes. Second, gene editing of hepatocytes to decrease misfolded protein results in expansion of corrected cells and amelioration of liver disease.

• Publisher: Elsevier Inc,Elsevier Limited,American Society of Gene & Cell Therapy
• Subject: A1AT / AAT / AATD / AAV / Advisors / Alleles / alpha 1-Antitrypsin - genetics / alpha 1-Antitrypsin - metabolism / alpha 1-Antitrypsin Deficiency - enzymology / alpha 1-Antitrypsin Deficiency - genetics / alpha 1-Antitrypsin Deficiency - pathology / alpha 1-Antitrypsin Deficiency - therapy / Animals / Apoptosis / Cirrhosis / Dependovirus - genetics / Dependovirus - metabolism / Disease Models, Animal / Elastase / Elastin / Gene Editing / Gene Expression / Gene Silencing / Gene therapy / Genetic Therapy - methods / Genetic Vectors - chemistry / Genetic Vectors - metabolism / Genome editing / Genomes / Graft Survival / Hepatocytes / Hepatocytes - enzymology / Hepatocytes - pathology / Hepatocytes - transplantation / humanized liver mouse model / Humans / Inventors / Laboratories / Liver cancer / Liver cirrhosis / Liver diseases / liver regeneration / liver xenograft / Lung diseases / Male / Mice / Mice, Inbred NOD / MicroRNAs - genetics / MicroRNAs - metabolism / miRNA / Missense mutation / Mutation / nuclease-free genome editing / Original / Patients / Polymerization / Protein folding / Proteins / RNAi / shRNA / Transgenes / Transplantation, Heterologous / Transplants & implants / Xenografts / α-1 antitrypsin deficiency